SAN FRANCISCO, CA -- (Marketwired) -- 03/07/18 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced receiving a Notice of Allowance from the

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/05/18 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that  Shawn Singh, Chief Executive

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/27/18 --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that Shawn Singh, Chief Executive

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/12/18 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) , a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported financial results for its

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/29/18 --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today issued a letter to stockholders as

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/22/18 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that  Shawn Singh, Chief

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/03/18 --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S.

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/18/17 --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that it will present at the

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/13/17 --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/11/17 --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system disorders, today announced